Roche’s Mabthera faces cut-price competition in EU
Blockbuster likely to face cheap near-copy for first time.
X
Roche’s Mabthera faces cut-price competition in EU
https://pharmaphorum.com/news/roches-mabthera-faces-cut-price-competition-eu/
Rheumatoid arthritis
EU regulators back Lilly’s blockbuster RA pill
Pill could generate $2 billion sales.
Ablynx in talks with partners for RA drug
Biotech suffered setback after AbbVie decided against partnership.
Sanofi/Regeneron RA drug rejected in US
FDA has concerns over Sanofi manufacturing plant.
J&J says ready to fend off Remicade competitor
Pfizer’s rival launch should be considered “at risk”, says J&J
Pfizer set for US launch of Remicade biosimilar
Pfizer gearing up for US launch late next month.
GSK/Janssen’s rheumatoid arthritis drug filed in EU
Drug could compete against Sanofi rival if approved.
Sandoz’s Enbrel biosimilar approved in US
FDA approves first near-copy of inflammatory diseases drug.